Effect of febuxostat on disease progression in patients of chronic kidney disease with high uric acid levels in the blood.
Phase 4
Completed
- Conditions
- Health Condition 1: N189- Chronic kidney disease, unspecifiedHealth Condition 2: null- Patients with Chronic Kidney disease stage 3/4
- Registration Number
- CTRI/2014/08/004853
- Lead Sponsor
- Institute of Postgraduate Medical Education and Research Kolkata
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 93
Inclusion Criteria
(1)CKD stages 3 and 4 as determined by calculated creatinine clearances.
(2)Serum uric acid level more than 6 mg/dl
Exclusion Criteria
1.requirement of medication (excluding diuretics) or conditions which may increase uric acid levels, such as disorders of primary uric acid metabolism. 2.autosomal dominant polycystic kidney disease
3. Patients with pregnancy, lactation
4. Symptomatic hyperuricemia or gout were also excluded from the trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The proportion of patients showing a greater than 10% decline of eGFR from baseline in the study and control populations.Timepoint: 6 months
- Secondary Outcome Measures
Name Time Method 1.The change in estimated glomerular filtration rate in the two groups from the baseline and at the end of the study period.Timepoint: 6 months;cardiovascular events (myocardial infarction, strokes or heart failure),Timepoint: 6 months;death due to any causeTimepoint: 6 months;development of CKD-V stage (drop in eGFR below 15 ml/min)Timepoint: 6 months;Uric acid levels in the study and control populationTimepoint: 6 months;development of any drug related adverse eventsTimepoint: 6 months